Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
McKinsey
McKesson
Johnson and Johnson

Last Updated: January 17, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TOPROL-XL

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Toprol-xl

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00038077 ↗ Reversal of Ventricular Remodeling With Toprol-XL Completed AstraZeneca Phase 3 2001-08-01 The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
NCT00123903 ↗ COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria Terminated GlaxoSmithKline Phase 3 2005-07-01 This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
NCT00241904 ↗ Reducing Total Cardiovascular Risk in an Urban Community Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 4 2006-05-01 PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.
NCT00241904 ↗ Reducing Total Cardiovascular Risk in an Urban Community Completed Johns Hopkins University Phase 4 2006-05-01 PLEASE NOTE: THIS STUDY IS ONLY ENROLLING PATIENTS CURRENTLY BEING TREATED AT BELAIR-EDISON FAMILY HEALTH CENTER. The purpose of this study is to compare the clinical effectiveness and cost effectiveness of two cardiovascular risk reduction programs - a comprehensive intensive (Cl) intervention with a less intensive (LI) intervention - in African American, and white low-income patients with known excessive cardiovascular disease risk.
NCT00255502 ↗ 307B - Safety, Tolerability and Pharmacokinetics Study of TOPROL-XL® in Hypertensive Pediatric Subjects Completed AstraZeneca Phase 3 2002-07-01 This was a 52-week, multicenter, open-label study to determine the safety, tolerability and pharmacokinetics of TOPROL-XL (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to 12 years < Tanner Stage 3) and adolescents (> 12 years old or > Tanner Stage 3 to 16 years old) of both genders. Because response to some therapies in adult hypertension appears to be different in black and non-black populations, the recruitment will have a mixture of black and non-black subjects. Pharmacokinetic measurements were performed on a subset of patients. Thirty subjects (15 subjects each in the 6 to 12 year age group and the 13 to 16 year age group) had a series of blood samples drawn. All subjects had a trough plasma level taken 24 hours after the last dose of open-label metoprolol CR/XL (Visit 18) with the exception of those subjects who completed Protocol 307B (16 week open-label treatment).
NCT00255528 ↗ Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects Completed AstraZeneca Phase 3 2002-07-01 This was a 4-week, multicenter, double-blind, placebo-controlled, randomized, parallel-group study to determine the antihypertensive dose range, efficacy, safety and tolerability of TOPROL-XL ® (metoprolol succinate) extended-release tablets (metoprolol CR/XL) in hypertensive pediatric subjects. The study population included school age children (age 6 to < Tanner Stage 3) and adolescents (> Tanner Stage 3 to age 16) of both genders. No more than 50% of the randomized subjects could be adolescents (> Tanner Stage 3 to 16 years old). Since response to some therapies in adult hypertension appears to be different in black and non-black populations, recruitment was aimed at a mixture of black and non-black children. The design included a 1-week screening period (for treatment naive subjects), a 1-week single-blind placebo run-in period, and a 4-week double-blind treatment period. Eligible subjects were randomized to the double-blind period with a once daily oral dose of metoprolol CR/XL to one of three target doses: 0.2, 1.0 and 2.0 mg/kg, or placebo. Dosing was weight adjusted. The dose range for this study was 12.5 to 200 mg daily. Subjects were closely monitored and evaluated at the end of Weeks 1, 2, 3 and 4 during the double-blind treatment period.
NCT00273052 ↗ COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension Completed GlaxoSmithKline Phase 3 2006-01-05 This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Toprol-xl

Condition Name

Condition Name for Toprol-xl
Intervention Trials
Hypertension 8
Diabetes Mellitus 2
Fasting 2
Healthy 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Toprol-xl
Intervention Trials
Hypertension 10
Heart Failure 4
Diabetes Mellitus 2
Atrial Fibrillation 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Toprol-xl

Trials by Country

Trials by Country for Toprol-xl
Location Trials
United States 162
Canada 17
India 5
Puerto Rico 2
Dominican Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Toprol-xl
Location Trials
Ohio 8
Florida 8
Pennsylvania 8
New York 8
North Carolina 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Toprol-xl

Clinical Trial Phase

Clinical Trial Phase for Toprol-xl
Clinical Trial Phase Trials
Phase 4 5
Phase 3 7
Phase 2 2
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Toprol-xl
Clinical Trial Phase Trials
Completed 17
Terminated 3
Unknown status 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Toprol-xl

Sponsor Name

Sponsor Name for Toprol-xl
Sponsor Trials
AstraZeneca 4
IPCA Laboratories Ltd. 3
Dr. Reddy's Laboratories Limited 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Toprol-xl
Sponsor Trials
Industry 20
Other 11
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
Moodys
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.